Immunotherapies for COVID-19: lessons learned from sepsis

Affiliations

¹ Departments of Pediatrics and Internal Medicine, Washington University School of Medicine, St Louis, MO, USA.
² Department of Surgery, University of Florida College of Medicine, Gainesville, FL 32610-0108, USA.
³ INSERM CIC-1435, Dupuytren University Hospital, Limoges, France; Intensive Care Unit, Dupuytren University Hospital, Limoges, France; INSERM UMR-1092, Université Limoges, Limoges, France.
⁴ Cohen Children's Medical Center, Northwell Health, Feinstein Institute for Medical Research, Zucker-Hofstra School of Medicine, Manhasset, NY, USA.
⁵ Cellular Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France.
⁶ INSERM CIC-1435, Dupuytren University Hospital, Limoges, France; UMR CNRS-7276 INSERM-1262, Limoges University, Limoges, France.
⁷ Department of Critical Care Medicine, St Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium.
⁸ Departments of Anesthesiology, Medicine, and Surgery, Washington University School of Medicine, St Louis, MO 63110-1093, USA. Electronic address: richardshotchkiss@wustl.edu.
⁹ Department of Surgery, University of Florida College of Medicine, Gainesville, FL 32610-0108, USA. Electronic address: lyle.moldawer@surgery.ufl.edu.

Review

Kenneth E Remy et al. Lancet Respir Med. 2020 Oct.

. 2020 Oct;8(10):946-949.

doi: 10.1016/S2213-2600(20)30217-4. Epub 2020 Apr 28.

¹ Departments of Pediatrics and Internal Medicine, Washington University School of Medicine, St Louis, MO, USA.
² Department of Surgery, University of Florida College of Medicine, Gainesville, FL 32610-0108, USA.
³ INSERM CIC-1435, Dupuytren University Hospital, Limoges, France; Intensive Care Unit, Dupuytren University Hospital, Limoges, France; INSERM UMR-1092, Université Limoges, Limoges, France.
⁴ Cohen Children's Medical Center, Northwell Health, Feinstein Institute for Medical Research, Zucker-Hofstra School of Medicine, Manhasset, NY, USA.
⁵ Cellular Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France.
⁶ INSERM CIC-1435, Dupuytren University Hospital, Limoges, France; UMR CNRS-7276 INSERM-1262, Limoges University, Limoges, France.
⁷ Department of Critical Care Medicine, St Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium.
⁸ Departments of Anesthesiology, Medicine, and Surgery, Washington University School of Medicine, St Louis, MO 63110-1093, USA. Electronic address: richardshotchkiss@wustl.edu.
⁹ Department of Surgery, University of Florida College of Medicine, Gainesville, FL 32610-0108, USA. Electronic address: lyle.moldawer@surgery.ufl.edu.

No abstract available

Figures

Immunotherapies for COVID-19: Restoring the immunity could be the priority.
Allaouchiche B. Allaouchiche B. Anaesth Crit Care Pain Med. 2020 Jun;39(3):385. doi: 10.1016/j.accpm.2020.05.009. Epub 2020 May 20. Anaesth Crit Care Pain Med. 2020. PMID: 32499129 Free PMC article. No abstract available.

1. Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019;15:813–822. - PMC - PubMed
1. Le RQ, Li L, Yuan W, et al. FDA Approval Summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23:943–947. - PMC - PubMed
1. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39:517–528. - PubMed
1. Giamarellos-Bourboulis EJ. Failure of treatments based on the cytokine storm theory of sepsis: time for a novel approach. Immunotherapy. 2013;5:207–209. - PubMed
1. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020 doi: 10.1002/jmv.25801. published online April 6. - DOI - PMC - PubMed